What Does the Research Say About Tysabri and PML?

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Information to Specialized Risk Awareness

If you or a loved one is taking Tysabri, you may be concerned about the risk of progressive multifocal leukoencephalopathy (PML). This concern is rooted in decades of pharmacovigilance and clinical research that has documented the association between immunomodulatory therapies and opportunistic infections. This page summarizes key findings from published reports and FDA labeling to help you understand the current evidence.

Tysabri and the Risk of Progressive Multifocal Leukoencephalopathy

Building on the legacy of general health information, this section focuses on the specific risks associated with Tysabri (natalizumab), a monoclonal antibody used for multiple sclerosis and Crohn's disease. Tysabri carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic viral infection of the brain caused by the JC virus (JCV). The U.S. Food and Drug Administration (FDA) has issued a boxed warning stating that Tysabri increases the risk of PML, which usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This warning is based on clinical evidence and adverse event reports. PML is a demyelinating disease that primarily affects immunocompromised individuals. A retrospective national cohort study of 456 PML cases observed between 1987 and 2024 described its clinical and laboratory characteristics, noting that PML can present with a range of neurological symptoms (https://pubmed.ncbi.nlm.nih.gov/40922664/). In Tysabri-treated patients, PML typically manifests as progressive neurological deficits, including cognitive impairment, motor weakness, and visual disturbances. The FDA Adverse Event Reporting System (FAERS) database lists fatigue, multiple sclerosis relapse, headache, gait disturbance, and memory impairment among the most frequently reported adverse events associated with Tysabri (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI). While these symptoms are not specific to PML, they underscore the importance of vigilant monitoring.

Mechanism and Risk Factors for PML in Tysabri-Treated Patients

The mechanistic pathway linking Tysabri to PML involves its pharmacological action. Tysabri is an alpha-4 integrin antagonist that inhibits lymphocyte migration into the central nervous system. This immunosuppressive effect can reactivate latent JCV, leading to PML. The FDA has identified three key risk factors for PML in Tysabri-treated patients: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered when initiating and continuing therapy. The adequacy of warnings regarding Tysabri and PML is a critical risk anchor. The FDA's boxed warning explicitly states that Tysabri increases PML risk and that healthcare professionals should monitor patients for any new signs or symptoms suggestive of PML. The warning also mandates that Tysabri dosing be withheld immediately at the first sign or symptom suggestive of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Despite these warnings, some patients may develop PML before symptoms are recognized, leading to severe outcomes. This raises questions about whether the warnings are sufficiently clear and whether healthcare providers are adequately educating patients about PML risks.

Legal Considerations for Patients Affected by Tysabri-Related PML

For affected patients, attorney-related considerations are important. Patients who develop PML after Tysabri treatment may seek legal recourse if they believe the warnings were inadequate or if their healthcare provider failed to monitor them appropriately. The timeline between Tysabri exposure and documented harm is a key factor in such cases. PML can occur months to years after starting Tysabri, with risk increasing after two years of therapy. Patients who experience PML may face significant medical costs, disability, and loss of quality of life. Legal claims may focus on whether the manufacturer provided sufficient warnings about PML risk and whether healthcare providers followed monitoring guidelines. In summary, Tysabri is associated with a well-documented risk of PML, a severe and often fatal brain infection. The FDA has issued a boxed warning highlighting this risk and identifying key risk factors. Patients and healthcare providers must remain vigilant for PML symptoms, and any suspected cases should prompt immediate discontinuation of Tysabri. For affected patients, legal considerations may arise regarding the adequacy of warnings and the timeline of harm. Understanding these factors is essential for informed decision-making and risk management.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the risk of PML with Tysabri treatment?

Tysabri (natalizumab) increases the risk of progressive multifocal leukoencephalopathy (PML), a severe brain infection caused by the JC virus. The FDA has issued a boxed warning stating that PML usually leads to death or severe disability. Risk factors include presence of anti-JCV antibodies, treatment duration beyond two years, and prior immunosuppressant use. (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962)

What legal options are available for patients who developed PML after Tysabri?

Patients who develop PML after Tysabri treatment may pursue legal claims if they believe the manufacturer's warnings were inadequate or if healthcare providers failed to monitor appropriately. Legal cases often focus on the adequacy of risk communication and adherence to monitoring guidelines. Affected individuals should consult an attorney experienced in pharmaceutical litigation.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.